Organogenesis Hldgs Q3 2024 Adj. EPS $0.10 Beats $(0.01) Estimate, Sales $115.177M Beat $108.833M Estimate
Organogenesis Hldgs Q3 2024 Adj. EPS $0.10 Beats $(0.01) Estimate, Sales $115.177M Beat $108.833M Estimate
Organogenesis控股2024年第三季調整每股收益$0.10，超過$(0.01)的預期，銷售額11517.7萬美元，超出預期的10883.3萬美元。
Organogenesis Hldgs (NASDAQ:ORGO) reported quarterly earnings of $0.10 per share which beat the analyst consensus estimate of $(0.01) by 1100 percent. This is a 150 percent increase over earnings of $0.04 per share from the same period last year. The company reported quarterly sales of $115.177 million which beat the analyst consensus estimate of $108.833 million by 5.83 percent. This is a 6.12 percent increase over sales of $108.530 million the same period last year.
Organogenesis控股（納斯達克：ORGO）報告每股盈利爲0.10美元，超過分析師共識估計的（0.01）美元1100％。這比去年同期每股盈利0.04美元增長150％。公司報告的季度銷售額爲11517.7萬美元，超過分析師共識估計的10883.3萬美元5.83％。這比去年同期的10853萬美元銷售額增長6.12％。